The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, is considering granting sublicensable patent licenses to Simon Fraser University in Canada and Le Centre National de la Recherche Scientifique in France. These licenses relate to a technology involving fluorescent RNA-fluorophore complexes, useful for studying RNA in live cells. The aim is to consolidate patent rights to expedite the development and marketing of this technology. Interested parties can submit comments or license applications by March 16, 2021, to object to the granting of the exclusive patent license.
Simple Explanation
The government is thinking about letting a university in Canada and a science group in France use their special idea that helps scientists see tiny parts of cells. This decision might make it easier for them to make new products, but some people are worried because it might not be fair or clear about how this affects costs and competition.